{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:50:09Z","timestamp":1790880609523,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/bmt.2017.205","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T13:41:32Z","timestamp":1508161292000},"page":"29-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin\u2019s and non-Hodgkin\u2019s B-cell lymphoma"],"prefix":"10.1038","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-289X","authenticated-orcid":false,"given":"E","family":"Joffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Rozovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Kirgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Trestman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Aviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Sarid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kolomansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gepstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Herishanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Naparstek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"BFbmt2017205_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 1995; 333: 1540\u20131545.","journal-title":"N Engl J Med"},{"key":"BFbmt2017205_CR2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.bbmt.2007.06.003","volume":"13","author":"NS Majhail","year":"2007","unstructured":"Majhail NS, Ness KK, Burns LJ, Sun C-L, Carter A, Francisco L et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007; 13: 1153\u20131159.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017205_CR3","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/cncr.23281","volume":"112","author":"JA Jones","year":"2008","unstructured":"Jones JA, Qazilbash MH, Shih Y-CT, Cantor SB, Cooksley CD, Elting LS . In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer 2008; 112: 1096\u20131105.","journal-title":"Cancer"},{"key":"BFbmt2017205_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"Y-B Chen","year":"2015","unstructured":"Chen Y-B, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1046\u20131053.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017205_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.bmt.1705744","volume":"40","author":"HF Fernandez","year":"2007","unstructured":"Fernandez HF, Escal\u00f3n MP, Pereira D, Lazarus HM . Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 2007; 40: 505\u2013513.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017205_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","volume":"20","author":"MD Caballero","year":"1997","unstructured":"Caballero MD, Rubio V, Rifon J, Heras I, Garc\u00eda-Sanz R, V\u00e1zquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451\u2013458.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017205_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bbmt.2010.07.008","volume":"17","author":"DM Oliansky","year":"2011","unstructured":"Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011; 17: 20\u201347.e30.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2017205_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2012.076075","volume":"98","author":"E Schorb","year":"2013","unstructured":"Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013; 98: 765\u2013770.","journal-title":"Haematologica"},{"key":"BFbmt2017205_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/bmt.2015.273","volume":"51","author":"L Sellner","year":"2016","unstructured":"Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant 2016; 51: 212\u2013218.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017205_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/CJI.0b013e3181c810b6","volume":"33","author":"A Nagler","year":"2010","unstructured":"Nagler A, Berger R, Ackerstein A, Czyz JA, Diez-Martin JL, Naparstek E et al. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation. J Immunother 2010; 33: 326\u2013333.","journal-title":"J Immunother"},{"key":"BFbmt2017205_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2017205_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE . Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165: 710\u2013718.","journal-title":"Am J Epidemiol"},{"key":"BFbmt2017205_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1179\/102453312X13221316477534","volume":"17","author":"M Di Ianni","year":"2012","unstructured":"Di Ianni M, Ballanti S, Iodice G, Reale A, Falzetti F, Minelli O et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin\u2019s lymphoma. Hematology 2012; 17: 23\u201327.","journal-title":"Hematology"},{"key":"BFbmt2017205_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10238-011-0157-2","volume":"12","author":"F Falzetti","year":"2012","unstructured":"Falzetti F, Di Ianni M, Ballanti S, Iodice G, Reale A, Minelli O et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med 2012; 12: 165\u2013171.","journal-title":"Clin Exp Med"},{"key":"BFbmt2017205_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/bmt.2016.275","volume":"52","author":"N Shah","year":"2017","unstructured":"Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M et al. Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). Bone Marrow Transplant 2017; 52: 321\u2013322.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2017205_CR16","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1080\/10428190802340184","volume":"49","author":"R Zaucha","year":"2008","unstructured":"Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D et al. High-dose chemotherapy with BEAM or Busulphan\/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008; 49: 1899\u20131906.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2017205_CR17","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1080\/10428190410001723250","volume":"45","author":"F Waheed","year":"2004","unstructured":"Waheed F, Kancherla R, Seiter K, Liu D, Qureshi Z, Hoang A et al. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Leuk Lymphoma 2004; 45: 2253\u20132259.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2017205_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3109\/10428194.2013.806659","volume":"55","author":"T Bains","year":"2014","unstructured":"Bains T, Chen AI, Lemieux A, Hayes-Lattin BM, Leis JF, Dibb W et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed\/refractory Hodgkin lymphoma. Leuk Lymphoma 2014; 55: 583\u2013587.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2017205_CR19","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1080\/10428194.2016.1185785","volume":"57","author":"A Isidori","year":"2016","unstructured":"Isidori A, Christofides A, Visani G . Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 2016; 57: 2499\u20132509.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2017205_CR20","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood-2014-08-596668","volume":"124","author":"G Visani","year":"2014","unstructured":"Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 2014; 124: 3029\u20133031.","journal-title":"Blood"},{"key":"BFbmt2017205_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jgo.2015.04.005","volume":"6","author":"E Hermet","year":"2015","unstructured":"Hermet E, Cabrespine A, Gui\u00e8ze R, Garnier A, Tempescul A, Lenain P et al. Autologous hematopoietic stem cell transplantation in elderly patients (\u2265 70 years) with non-Hodgkin\u2019s lymphoma: a French Society of bone marrow transplantation and cellular therapy retrospective study. J Geriatr Oncol 2015; 6: 346\u2013352.","journal-title":"J Geriatr Oncol"},{"key":"BFbmt2017205_CR22","first-page":"1","volume":"8","author":"N Sarid","year":"2015","unstructured":"Sarid N, Joffe E, Gibstein L, Avivi I, Polliack A, Perry C et al. Reduced-dose ICE chemotherapy\u00b1rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2015; 8: 1\u20137.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2017205_CR23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V128.22.678.678","volume":"128","author":"I S\u00e1nchez-Ortega","year":"2016","unstructured":"S\u00e1nchez-Ortega I, Basak GW, Beohou E, van der Werf S, Labopin M, van Biezen A et al. Autologous hematopoietic cell transplantation in elderly patients aged 65 and older: a retrospective analysis by the complications and quality of life working party of the EBMT. Blood 2016; 128: 678.","journal-title":"Blood"},{"key":"BFbmt2017205_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11912-015-0465-x","volume":"17","author":"OB Lahoud","year":"2015","unstructured":"Lahoud OB, Sauter CS, Hamlin PA, Dahi PB . High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma. Curr Oncol Rep 2015; 17: 42.","journal-title":"Curr Oncol Rep"},{"key":"BFbmt2017205_CR25","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3324\/haematol.13273","volume":"93","author":"E Jantunen","year":"2008","unstructured":"Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008; 93: 1837\u20131842.","journal-title":"Haematologica"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2017205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2017205","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2017205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:37:29Z","timestamp":1648064249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2017205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFbmt2017205"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.205","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]},"assertion":[{"value":"6 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}